The full names of Ora and Nira are Olaparib and Niraparib respectively, which are suitable for the treatment of HRD-positive patients with ovarian cancer, as they are targeted drugs for ovarian cancer, which can significantly improve the therapeutic effect of ovarian cancer, but both of them have their own advantages and disadvantages in terms of price, efficacy and side effects. 1.Price: . Olaparib is a domestic listed drug, the price is relatively low; Niraparib is not listed in China, the price is relatively high. 2. Efficacy: Olaparib has more targets, less off-target effect and less resistance, which is not only effective for patients with BRCA gene mutation, but also effective for patients without BRCA gene mutation; Niraparib has fewer targets, only 2, which is not superior in terms of resistance, but its efficacy is stronger for ovarian cancer with unknown BRCA gene mutation, which has been proved in phase III clinical trial. 3. Side effects: Olaparib has mild side effects, mainly manifested as nausea, vomiting, diarrhea, etc., and is less likely to produce serious side effects; Niraparib has big side effects, the most common of which is hematotoxicity, which is manifested as anemia, leukopenia, thrombocytopenia, etc., and is the main reason for its dosage reduction and discontinuation. To summarize, whether to choose olaparib or niraparib for HRD-positive patients with ovarian cancer should be considered comprehensively, and the drug should be used under the guidance of specialists in order to strive for the best therapeutic effect.